Date | Time | Source | Headline | Symbol | Company |
05/21/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer | EU:VLA | Valneva SE |
05/21/2024 | 1:00AM | GlobeNewswire Inc. | Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur Scientifique | EU:VLA | Valneva SE |
05/21/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer | EU:VLA | Valneva SE |
05/13/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine | EU:VLA | Valneva SE |
05/13/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine | EU:VLA | Valneva SE |
05/13/2024 | 1:00AM | GlobeNewswire Inc. | Valneva annonce de nouveaux résultats positifs chez les adolescents pour l’étude pivot de Phase 3 de son vaccin à dose unique contre le chikungunya | EU:VLA | Valneva SE |
05/07/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates | EU:VLA | Valneva SE |
05/07/2024 | 1:00AM | GlobeNewswire Inc. | Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités | EU:VLA | Valneva SE |
05/07/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates | EU:VLA | Valneva SE |
05/06/2024 | 1:30AM | GlobeNewswire Inc. | Declaration of shares and voting rights April 30, 2024 - VALNEVA SE | EU:VLA | Valneva SE |
05/06/2024 | 1:30AM | GlobeNewswire Inc. | Déclaration d’actions et de droits de vote - 30 avril 2024 - Valneva SE | EU:VLA | Valneva SE |
04/04/2024 | 12:00PM | GlobeNewswire Inc. | Déclaration d'actions et de droits de vote de la société Valneva SE - mars 2024 | EU:VLA | Valneva SE |
04/04/2024 | 12:00PM | GlobeNewswire Inc. | Declaration of voting rights - Valneva SE, March 2024 | EU:VLA | Valneva SE |
03/26/2024 | 2:00AM | GlobeNewswire Inc. | Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate | EU:VLA | Valneva SE |
03/26/2024 | 2:00AM | GlobeNewswire Inc. | Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate | EU:VLA | Valneva SE |
03/26/2024 | 2:00AM | GlobeNewswire Inc. | Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika | EU:VLA | Valneva SE |
03/25/2024 | 2:00AM | GlobeNewswire Inc. | Valneva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son rapport annuel américain « Form 20-F » | EU:VLA | Valneva SE |
03/25/2024 | 2:00AM | GlobeNewswire Inc. | Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F | EU:VLA | Valneva SE |
03/25/2024 | 2:00AM | GlobeNewswire Inc. | Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F | EU:VLA | Valneva SE |
03/21/2024 | 2:00AM | GlobeNewswire Inc. | Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. | EU:VLA | Valneva SE |
03/21/2024 | 2:00AM | GlobeNewswire Inc. | Valneva fera une présentation sur son vaccin contre le chikungunya, IXCHIQ®, et participera à plusieurs événements lors du 24ème World Vaccine Congress à Washington, D.C. | EU:VLA | Valneva SE |
03/21/2024 | 2:00AM | GlobeNewswire Inc. | Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. | EU:VLA | Valneva SE |
03/20/2024 | 2:00AM | GlobeNewswire Inc. | Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook | EU:VLA | Valneva SE |
03/18/2024 | 2:00AM | GlobeNewswire Inc. | Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed | EU:VLA | Valneva SE |
03/18/2024 | 2:00AM | GlobeNewswire Inc. | Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed | EU:VLA | Valneva SE |
03/18/2024 | 2:00AM | GlobeNewswire Inc. | Valneva annonce un report de la date de début de remboursement du prêt contracté avec les sociétés Deerfield et OrbiMed | EU:VLA | Valneva SE |
03/06/2024 | 2:30AM | GlobeNewswire Inc. | Déclaration d’actions et de droits de vote de la société Valneva - 29 février 2024 | EU:VLA | Valneva SE |
03/06/2024 | 2:30AM | GlobeNewswire Inc. | VALNEVA Declaration of shares and voting rights - February 29, 2024 | EU:VLA | Valneva SE |
03/04/2024 | 1:00AM | GlobeNewswire Inc. | Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences | EU:VLA | Valneva SE |
03/04/2024 | 1:00AM | GlobeNewswire Inc. | Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences | EU:VLA | Valneva SE |